{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:46:16Z","timestamp":1788921976839,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"am","delay-in-days":311,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA237154"],"award-info":[{"award-number":["R01CA237154"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bmc.2025.118136","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T19:17:53Z","timestamp":1740683873000},"page":"118136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Fatty acid binding protein 5 inhibitors as novel anticancer agents against metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"122","author":[{"given":"Hehe","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanzhou","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manojit M.","family":"Swamynathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhra","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalani","family":"Jayanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Rendina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Bogdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaczocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd C.","family":"Trotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka B.","family":"Bialkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3628-1161","authenticated-orcid":false,"given":"Iwao","family":"Ojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118136_b0005","unstructured":"Survival Rates for Prostate Cancer, https:\/\/www.cancer.org\/cancer\/prostate-cancer\/detection-diagnosis-staging\/survival-rates.html."},{"key":"10.1016\/j.bmc.2025.118136_b0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.bmc.2025.118136_b0015","doi-asserted-by":"crossref","first-page":"9322","DOI":"10.18632\/oncotarget.6975","article-title":"Fatty acid activated PPAR\u03b3 promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter","volume":"7","author":"Forootan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2025.118136_b0020","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9456020","article-title":"Crosstalk between the androgen receptor and PPAR gamma signaling pathways in the prostate","volume":"2017","author":"Olokpa","year":"2017","journal-title":"PPAR Res"},{"key":"10.1016\/j.bmc.2025.118136_b0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013500","article-title":"Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models","volume":"5","author":"Marques","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2025.118136_b0030","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/jnci\/djr362","article-title":"Novel therapies for metastatic castrate-resistant prostate cancer","volume":"103","author":"Dayyani","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bmc.2025.118136_b0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ctrv.2017.04.008","article-title":"Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer","volume":"57","author":"Galletti","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bmc.2025.118136_b0040","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1111\/cas.13729","article-title":"Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer","volume":"109","author":"Hongo","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bmc.2025.118136_b0045","article-title":"The biological functions and regulatory mechanisms of fatty acid binding protein 5 in various diseases","volume":"10","author":"Xu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.bmc.2025.118136_b0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55418-x","article-title":"FABP5 coordinates lipid signaling that promotes prostate cancer metastasis","volume":"9","author":"Carbonetti","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118136_b0055","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/pcmedi\/pbz015","article-title":"Fatty acid-binding protein 5 (FABP5)-related signal transduction pathway in castration-resistant prostate cancer cells: a potential therapeutic target","volume":"2","author":"Naeem","year":"2019","journal-title":"Precis Clin Med"},{"key":"10.1016\/j.bmc.2025.118136_b0060","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/jcp.26762","article-title":"FABP5 is a critical regulator of methionine- and estrogen-induced SREBP-1c gene expression in bovine mammary epithelial cells","volume":"234","author":"Li","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.bmc.2025.118136_b0065","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1158\/0008-5472.CAN-13-0384","article-title":"Genetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis","volume":"73","author":"Levi","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118136_b0070","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/234629","article-title":"Involvement of fatty acid binding protein 5 and PPARbeta\/delta in prostate cancer cell growth","volume":"2010","author":"Morgan","year":"2010","journal-title":"PPAR Res"},{"key":"10.1016\/j.bmc.2025.118136_b0075","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/BJ20150926","article-title":"The cancer-promoting gene fatty acid-binding protein 5 (FABP5) is epigenetically regulated during human prostate carcinogenesis","volume":"473","author":"Kawaguchi","year":"2016","journal-title":"Biochem J"},{"key":"10.1016\/j.bmc.2025.118136_b0080","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.18632\/oncotarget.3442","article-title":"Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor","volume":"6","author":"Powell","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2025.118136_b0085","doi-asserted-by":"crossref","DOI":"10.1038\/srep42961","article-title":"Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer","volume":"7","author":"Fujita","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118136_b0090","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00345-019-02651-8","article-title":"Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5","volume":"38","author":"Nitschke","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.bmc.2025.118136_b0095","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.7150\/jca.15860","article-title":"Proteomic upregulation of fatty acid synthase and fatty acid binding protein 5 and identification of cancer- and race-specific pathway associations in human prostate cancer tissues","volume":"7","author":"Myers","year":"2016","journal-title":"J Cancer"},{"key":"10.1016\/j.bmc.2025.118136_b0100","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9794","article-title":"Saturated fatty acids regulate retinoic acid signalling and suppress tumorigenesis by targeting fatty acid-binding protein 5","volume":"6","author":"Levi","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118136_b0105","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1080\/07391102.2017.1337591","article-title":"Molecular dynamics simulations of apo and holo forms of fatty acid binding protein 5 and cellular retinoic acid binding protein II reveal highly mobile protein, retinoic acid ligand, and water molecules","volume":"36","author":"Hunter","year":"2018","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.bmc.2025.118136_b0110","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1947601913499155","article-title":"A novel cutaneous Fatty Acid-binding protein-related signaling pathway leading to malignant progression in prostate cancer cells","volume":"4","author":"Bao","year":"2013","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bmc.2025.118136_b0115","doi-asserted-by":"crossref","first-page":"19106","DOI":"10.1074\/jbc.M109.099770","article-title":"Fatty acid-binding protein 5 and PPARbeta\/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth","volume":"285","author":"Kannan-Thulasiraman","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2025.118136_b0120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3892\/ijo.2013.2166","article-title":"The expression of C-FABP and PPARgamma and their prognostic significance in prostate cancer","volume":"44","author":"Forootan","year":"2014","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bmc.2025.118136_b0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2025.118136_b0130","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.bmc.2025.118136_b0135","doi-asserted-by":"crossref","first-page":"31753","DOI":"10.18632\/oncotarget.25878","article-title":"A novel fatty acid-binding protein 5-estrogen-related receptor \u03b1 signaling pathway promotes cell growth and energy metabolism in prosta","volume":"9","author":"Senga","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2025.118136_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050968","article-title":"Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs","volume":"7","author":"Berger","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2025.118136_b0145","doi-asserted-by":"crossref","first-page":"31041","DOI":"10.18632\/oncotarget.16055","article-title":"Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5","volume":"8","author":"Al-Jameel","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2025.118136_b0150","article-title":"Molecular mechanisms on how FABP5 inhibitors promote apoptosis-induction sensitivity of prostate cancer cells","author":"Zhang","year":"2023","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.bmc.2025.118136_b0155","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejmech.2018.04.050","article-title":"SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins","volume":"154","author":"Yan","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118136_b0160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/pros.23921","article-title":"Docetaxel\/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth","volume":"80","author":"Carbonetti","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.bmc.2025.118136_b0165","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/2159-8290.CD-13-0346","article-title":"RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis","volume":"4","author":"Cho","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2025.118136_b0170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/cancers16010060","article-title":"FABP5 inhibition against PTEN-mutant therapy resistant prostate cancer","volume":"16","author":"Swamynathan","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2025.118136_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094200","article-title":"Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia","volume":"9","author":"Kaczocha","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2025.118136_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106184","article-title":"SAR study on Novel truxillic acid monoester-based inhibitors of fatty acid binding proteins as next-generation antinociceptive agents","volume":"129","author":"Wang","year":"2022","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118136_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2024.01.335","article-title":"Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in oxalplatin-induced peripheral neuropathy","volume":"25","author":"Warren","year":"2024","journal-title":"J. Pain"},{"key":"10.1016\/j.bmc.2025.118136_b0190","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.4155\/fmc-2016-0093","article-title":"AutoQSAR: an automated machine learning tool for best-practice quantitative structure\u2013activity relationship modeling","volume":"8","author":"Dixon","year":"2016","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmc.2025.118136_b0195","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.4161\/cc.7.12.6166","article-title":"Targeting prostate cancer based on signal transduction and cell cycle pathways","volume":"7","author":"Lee","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bmc.2025.118136_b0200","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.06001","article-title":"AR, the cell cycle, and prostate cancer","volume":"6","author":"Balk","year":"2008","journal-title":"Nucl Recept Signal"},{"key":"10.1016\/j.bmc.2025.118136_b0205","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3941217","article-title":"Safety and efficacy of first-line treatments for chemotherapy-naive metastatic castration-resistant prostate cancer: a systematic review and indirect comparison","volume":"2017","author":"Zheng","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.bmc.2025.118136_b0210","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s10495-012-0776-4","article-title":"Fatty acid synthase inhibitor cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis","volume":"18","author":"Jeong","year":"2013","journal-title":"Apoptosis"},{"key":"10.1016\/j.bmc.2025.118136_b0215","first-page":"709","article-title":"Topotecan. A review of its potential in advanced ovarian cancer","volume":"56","author":"Brogden","year":"2012","journal-title":"Adis Drug Evaluation"},{"key":"10.1016\/j.bmc.2025.118136_b0220","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/TCRM.S1771","article-title":"A review of topotecan in combination chemotherapy for advanced cervical cancer","volume":"4","author":"Robati","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.bmc.2025.118136_b0225","doi-asserted-by":"crossref","DOI":"10.1038\/srep15437","article-title":"Topotecan for relapsed small-cell lung cancer: systematic review and meta-analysis of 1347 patients","volume":"5","author":"Horita","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118136_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000011923","article-title":"Topotecan - a novel topoisomerase I inhibitor: pharmacology and clinical experience","volume":"56","author":"Kollmannsberger","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.bmc.2025.118136_b0235","doi-asserted-by":"crossref","first-page":"429","DOI":"10.14740\/wjon950e","article-title":"Role of topotecan in non-small cell lung cancer: a review of literature","volume":"6","author":"Vennepureddy","year":"2015","journal-title":"World J Oncol"},{"key":"10.1016\/j.bmc.2025.118136_b0240","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/mp900243b","article-title":"Cancer therapies utilizing the camptothecins: a review of the in vivo literature","volume":"7","author":"Venditto","year":"2010","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmc.2025.118136_b0245","article-title":"A retrospective analysis of the effect of irinotecan-based regimens in patients with metastatic breast cancer previously treated with anthracyclines and taxanes","volume":"11","author":"Suo","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmc.2025.118136_b0250","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2025.118136_b0255","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2025.118136_b0260","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2025.118136_b0265","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinf"},{"key":"10.1016\/j.bmc.2025.118136_b0270","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2210990119","article-title":"Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein","volume":"119","author":"Yang","year":"2022","journal-title":"PNAS"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962500077X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962500077X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:57:19Z","timestamp":1762347439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808962500077X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":54,"alternative-id":["S096808962500077X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118136","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty acid binding protein 5 inhibitors as novel anticancer agents against metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118136"}}